Link between biological aging and type 2 diabetes risk in people with liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between biological aging and the incidence of type 2 diabetes mellitus (T2DM) in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will assess biological age using various methods, including phenotypic age and homeostatic dysregulation, and will employ statistical models to analyze the association between biological aging and T2DM risk. The study aims to clarify how biological aging may influence the development of T2DM in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Abdominal ultrasound data available in annual health check-up records
2. At least one of the following five metabolic indicators recorded annually:

(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)

Exclusion Criteria:

1. Age \<20 or \>90 years
2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)
3. Type 2 diabetes mellitus at baseline
4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)

Where it's running

• the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000
  Ningbo, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Lei Xu
• Email: xulei22@163.com
• Phone: +8613486659126

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lifestyle change program to help type 2 diabetes go into remission in Pakistan

  This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.

  Recruiting at 2 sites Green International University · Lahore, Punjab Province and 1 other locations · NCT07912944

• Health profile of MASLD in Kazakhstan and real-world use of Ursosan in Almaty

  This study tests how MASLD appears in adults in Kazakhstan and how Ursosan is used in real-world care for a subgroup in Almaty.

  Recruiting at 7 sites Kazakh Association of Internal Medicine Specialists · Aktobe, Aktobe and 6 other locations · NCT07889999

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• MWN105 injection in overweight or obese adults you may join

  This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Kunming, Yunnan · NCT07803809

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.